Navigation Links
Robbins & Myers to Present at Merrill Lynch Growth Industrials Conference December 13, 2007
Date:12/6/2007

DAYTON, Ohio, Dec. 6 /PRNewswire-FirstCall/ -- Robbins & Myers, Inc. (NYSE: RBN) announced today that it will present at the Merrill Lynch Growth Industrials Conference on December 13, 2007, in New York City. Presenting for the Company will be Peter C. Wallace, President and Chief Executive Officer, and Christopher M. Hix, Vice President and Chief Financial Officer.

The Company's presentation is scheduled for 10:00 a.m., EST, at the Merrill Lynch Downtown Headquarters, 250 Vesey Street, New York, NY. The slide presentation can be accessed through their website, http://www.robn.com, and will be posted to the "Investor Relations" section and available for 30 days.

Robbins & Myers, Inc. is a leading supplier of engineered equipment and systems for critical applications in global energy, industrial, chemical and pharmaceutical markets.


'/>"/>
SOURCE Robbins & Myers, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
2. Robbins & Myers Announces Regular Quarterly Cash Dividend
3. Robbins Bros. Gives Water at AIDS Walk L.A.
4. Robbins & Myers Presenting at Bear Stearns 3rd Annual Commodities and Capital Goods Conference November 28, 2007
5. Bristol-Myers Squibb Announces Dividend
6. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
7. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
8. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
9. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
10. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
11. American Cancer Society to Present Highest Honor to Matthew L. Myers, Douglas R. Lowy, and Mark Schiffman for Outstanding Contributions to Cancer Fight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from Guardian’s ... face in trying to balance both short-term and long-term benefits demands. Are ... the growing complexity, companies are finding that the short-term strategies used to control ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... ... 29, 2017 , ... AvePoint , the Microsoft Cloud expert, is pleased ... Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with ... S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, AvePoint ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the first technology to directly address the resolution to globally reduce the harmful ... a patented compound of FDA and TTB approved ingredients that when infused into ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017 Varian Medical Systems (NYSE: ... for the second quarter of fiscal year 2017 following the ... news release will be followed by a teleconference available to ... and a link to the conference call webcast will be ... access the teleconference call and replay: ...
(Date:3/29/2017)... , March 29, 2017   Royal Philips ... in health technology, and PathAI, a company that ... with the aim to develop solutions that improve ... cancer and other diseases. The partnership aims to ... this form of artificial intelligence to be applied ...
(Date:3/29/2017)... TEL AVIV, Israel , March 29, 2017 ... license agreement in which Exeltis will obtain exclusive marketing rights for ... ... is an age-appropriate drug targeted to treat sleep disorders in children ... to be the first sleep medication approved for children. ...
Breaking Medicine Technology: